Stay updated on Atrasentan in IgA Nephropathy Clinical Trial

Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.6.5, replacing the previous v3.6.4. This reflects a software version update rather than a modification to the study details.
    Difference
    0.0%
    Check dated 2026-08-11T19:17:48.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    A new bibliographic reference for the Endothelin System in Hypertension and CKD was added to Publications/References, and the page revision was updated to v3.6.4 (replacing v3.6.3).
    Difference
    0.0%
    Check dated 2026-07-28T12:27:17.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Added the final Lancet publication citation for the ALIGN IgA nephropathy results and removed the earlier online-ahead-of-print Lancet citation, updating the Publications section to reflect the final article.
    Difference
    0.0%
    Check dated 2026-07-14T09:26:14.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    A new publication citation by Kuo et al. on atrasentan and IgA nephropathy is added to Publications. The page revision is updated to v3.6.3, reflecting updated scholarly references and versioning for the ALIGN study.
    Difference
    0.0%
    Check dated 2026-06-30T00:34:16.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Adds a recruitment status note indicating the trial is no longer recruiting participants and includes new navigation items such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'; removes the old 'Intervention / Treatment' label in favor of 'Intervention/Treatment' and adds the site revision note 'Revision: v3.6.0'.
    Difference
    0.2%
    Check dated 2026-06-15T17:09:25.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    Novartis Pharmaceuticals is now listed as sponsor with new identifiers and drug details added. The study plan now includes an open-label atrasentan extension, a zigakibart substudy, and updated timelines including primary completion in 2028-04-14 and enrollment of 404 participants.
    Difference
    2%
    Check dated 2026-06-08T14:48:40.000Z thumbnail image

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.